Compare Ascendis Pharma A/S (ASND) vs Workiva Inc (WK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Workiva Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Workiva Inc trades at $52.99 (market cap $2.93B). The key difference: Ascendis Pharma A/S is far larger — about 6.1× Workiva Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| ASND | WK | |
|---|---|---|
Market Cap | $17.74B | $2.93B |
Sector | Health | Technology |
52-Week High | $277.18 | $93.31 |
52-Week Low | $163.32 | $44.31 |
Enterprise Value | $18.11B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Workiva (WK) trades at $52.17, down slightly by 0.31% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.77 surpassing estimates. Revenue growth is solid, projected to reach $926 million in 2026, though profitability remains thin with a net margin of 1.53%. Recent news highlights investor conference participation and AI integration in financial reporting.
The stock presents growth potential with a consensus price target of $71.00, implying significant upside. However, high valuation multiples (P/E of 217.38) and reliance on sustained earnings expansion pose risks. Competitive pressures in regulatory software and macroeconomic sensitivity could challenge future performance. Institutional ownership trends and continued execution on guidance will be critical for maintaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
